Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago
|
|
- Eustace Lawrence
- 7 years ago
- Views:
Transcription
1 Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago
2 Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease Related Therapy Related Improve quality of life Limit surgery? Cosnes et al. Inflamm Bowel Dis 2002; 8: 244
3 Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis Severe Surgery Infliximab MTX AZA/6-MP Systemic Steroids Budesonide Antibiotics 5-ASA Concept Obfuscates Induction/Maintenance Strategies Moderate Mild Surgery Cyclosporine Systemic Corticosteroids Infliximab Aminosalicylates
4 Conventional approach to Induction Therapy: step-up Natalizumab Anti TNF-α Disease severity Aminosalicylates Non-systemic corticosteroids Systemic corticosteroids Time Clinical approach to use mildest form of drug therapy to treat patients first Move to next step in non-responders
5 Step-up management approach Advantages Patients attain remission with less toxic therapies Potentially more toxic therapies reserved for more severe or refractory disease Minimizes risk of adverse events Cost sparing (short-term?) Disadvantages Patients have to earn most effective treatments Decrease in quality-of-life before patients obtain optimal therapy Likelihood of surgery is high Disease is not modified
6 IBDs are chronic, life-long long We cannot just look at the short-term induction therapy
7 Long-Term Therapy for IBD is Sequential Induction Maintenance
8 Impact of Therapy will Depend on Degree of Structural Damage & Velocity of Progression Cumulative Probability (%) High Potential Low Potential Penetrating Stricturing Inflammatory Months Patients at risk: n= Cosnes et al. Inflamm Bowel Dis 2002; 8: 244
9 Efficacy of AZA as Crohn s Disease Maintenance Therapy After Steroids in Adults * % Patients Not Failing Trial AZA 2.5 mg/kg per d Placebo 42% p= % Duration of Trial (months) Candy S, et al. Gut. 1995;37(4): *Remission induced by prednisolone tapered over 12 wk Inclusion: Patients were not steroid dependent
10 Efficacy of 6-MP 6 as Crohn s s Disease Maintenance Therapy After Steroids in Steroid-naïve Children % of Patients in Remission N= MP 91% Control P< % Days Since Remission Induction Markowitz J et al. Gastroenterology. 2000;119:895. At baseline, patients received prednisone plus either 6-MP or placebo. Steroids were tapered after induction of remission.
11 TNF:Fusion Fusion protein, antibodies and PEGylated Fab' fragment Three classes of anti-tnf:fusion protein, Etanercept Receptor Infliximab Fab Adalimumab Fab Certolizumab pegol IgG1 Fc IgG1 Fc PEG Human recombinant receptor/fc fusion protein Chimeric Monoclonal antibody Human PEGylated humanized Fab fragment 2 20 kda PEG Coutesy of Stephen B. Hanauer, M.D.
12 Clinical Trials with Anti-TNF Biologics in Refractory Crohn s s disease Drug Targan/Infliximab Classic I/Adalimumab Placebo ACCENT I/Infliximab CHARM/Adalimumab PRECiSE 2/Certolizumab Drug Responder Drug Placebo Maintenance Drug Response Maintenance CLASSIC II/Adalimumab PRECiSE1/Certolizumab Placebo
13 Patients (%) Comparing ACCENT I, CHARM, and PRECiSE 2 Results Week 4 Response Patients (%) CHARM** (adalimumab) 40 Week 26 Remission 58.5 Week 2 Response ACCENT I* (infliximab) Week 6 Response PRECiSE 2 (certolizumab pegol) 47.9 Week 26 Remission *5 mg/kg dose. **Maintenance trial with 80/40 mg induction dosing. Randomized responders = CR-70 at week 4. Week 26 remission among randomized responders on 40 mg every other week dosing. 24 Overall Remission Week Week 30 Remission Patients (%) 22.8 Overall Remission Week Overall Remission Week 26
14 Impact of Disease Duration
15 Clinical Remission at Weeks 26 by Disease Duration in adalimumab CHARM study Placebo All Adalimumab % of patients * 40 41** N=23 N=39 N=36 N=57 N=111 N=233 <2 years 2 to <5 years 5 years *p=0.002, **p<0.001, p=0.014, p=0.001 all vs placebo Schreiber S, et al. Gastroenterology 2007;132(4 Suppl 2):A-147
16 Week 26 Remission with certolizumab by Duration Of Crohn s s Disease In PRECiSE 2 100% 80% 68% Certolizumab Remission Placebo Remission 60% 40% 55% 37% 36% 47% 29% 44% 24% 20% 0% < 1 Year 1-2 Years 2-5 Years > 5 Years
17 Impact of Concomitant Immunomodulators
18 Comparable clinical outcomes with or without immunomodulators ACCENT I: Comparable clinical outcomes 100 With concomitant IMM Without concomitant IMM Patients (%) Week 30 Week 54 Week 30 Week 54 Response Remission Lichtenstein et al, Gastroenterology 2007; 132: A-146 (No. 982)
19 CHARM: Effect of concomitant adalimumab and immunosuppressive therapy on remission at week 26 and 56 Patients in remission (%) With IMM Without IMM Placebo Adalimumab 40 mg EOW, sc Adalimumab 40 mg q-weekly, sc Week 56 Remission defined as CDAI <150 Colombel et al, Gastroenterology 2007; 132: 52
20 Continuous vs interrupted use of immunomodulators in the long-term efficacy of infliximab (IFX): The IMID Trial No need for early rescue IFX: primary endpoint Cumulative survival Log Rank (Cox): 0735; Breslow: Median IFX levels, Week 8 to Week 104 combined IFX trough levels (μg) 100 p< Continued Discontinued Time (weeks) 0 Continued Discontinued 80 patients randomized to continue ( + CON, n=40) or to interrupt ( ++ DIS, n=40) immunomodulators (azathioprine or methotrexate) 6 months after the start of infliximab (5 mg/kg IV) Van Asche et al, Gastroenterology 2007; 132: A-103 (No. 734)
21 Recent Anti-TNF Biologic Trials Steroids Steroids IS Step-up/Top-down (Steroid-naïve) Infliximab + IS COMMITT (Steroid-induced, IS naive) SONIC (Steroid-refractory, IS naïve) Infliximab Infliximab + MTX Infliximab Infliximab + AZA AZA
22 Early Aggressive Biologic Therapy vs Conventional Management of Crohn s s Disease Newly diagnosed, antimetabolite, anti-tnf, or steroid-naïve CD patients (n=133) Steroids Steroids + AZA MTX + IFX Early aggressive (n=67) IFX (0,2,6 weeks) + AZA + (episodic) IFX Steroids Conventional therapy (n=66) D Haens et al. Lancet 2008;371:660
23 Step-Up vs. Top-Down: Results % of Patients % of Patients CDAI < 150 & No Steroids Steroid Use P = 0.03 P = Months 12 Months P < P < Months 12 Months D'Haens G, et al. Lancet 2008;371: Percent of Patients Treatment Success* From Week 14 Through 2 Years 29 P < Top Down Step Up *Remission (CDAI < 150), discontinuation of steroids and infliximab, and no resection. 5
24 Step Up vs. Top Down: Complete Endoscopic Remission at 2 Years 100 ** 73 **p=0.003 Patients (%) 30 0 (n=26) Early aggressive (n=23) Conventional therapy D Haens et al. Lancet 2008;371:660
25 COMMITT: MTX plus IFX in CD (1) Patients with active CD on corticosteroids within last 6 weeks 1:1 randomization to IFX + PBO (n=63) IFX + MTX (n=63) Steroids withdrawn by Week 14 per protocol IFX at 0, 2, and 6 weeks then maintenance q8w Primary analysis: time to treatment failure CDAI <150, no prednisone by Week 14 and maintained to Week 50 Relapse: CDAI increase of 70 points Feagan B, et al. DDW 2008: #682C
26 COMMITT: MTX plus IFX in CD (2) Patients in Remission off Steroids (%) p= p= Week 14 Week 50 MTX + IFX PBO + IFX No difference in ITT analysis, duration of disease <2 years, by CDAI score No difference in infectious AEs (58.7% MTX vs 61.9% PBO) Feagan B, et al. DDW 2008: #682C
27 SONIC Induction + maintenance of steroid-free remission, mucosal healing, IFX monotherapy vs IFX+AZA combination vs AZA monotherapy in moderate-to-severe CD in patients with no prior exposure to biologic agents and immunosuppressants Cosnes et al. Inflamm Bowel Dis 2002; 8: 244
28 Clinical remission without corticosteroids at week 26 Primary endpoint 100 Proportion of Patients (%) p=0.009 p< p= /170 75/169 96/169 AZA + placebo IFX + placebo IFX+ AZA Sandborn et al., ACG 2008 annual meeting, abstract #29
29 Mucosal healing at week 26 Secondary endpoint 100 Proportion of Patients (%) p=0.023 p< p= /109 28/93 47/107 AZA + placebo IFX + placebo IFX+ AZA Sandborn et al., ACG 2008 annual meeting, abstract #29
30 COMMITT vs. SONIC COMMITT SONIC Steroid-induced patients IS Naïve Steroid-Induced Forced steroid-taper by week 14 40% Steroid-dependent (refractory CDAI>250) IS Naïve Ad lib steroids to week 14 ( ) then taper Cosnes et al. Inflamm Bowel Dis 2002; 8: 244
31 Yin & Yang of Concomitant Immunomodulators All biologics are immunogenic Antibodies (at least to infliximab) Associated with acute/delayed infusion reactions Shorter duration of response (with episodic therapy) Immunomodulators reduce immunogenicity across all trials Yet No difference in short- or long-term responses to induction + maintenance therapy in refractory CD ACCENT,CHARM, PREcISE No benefit with steroidinduction (COMMIT) Positive Benefit in steroiddependent (SONIC) Increase long-term toxicity Serious infections Risk of neoplasia
32 Anti-TNF-α Risks Immunogenicity (all biologics) Infliximab specific Infusion reactions Class effect Drug-induced lupus Injection site reactions (adalimumab, certolizumab pegol) Non-Hodgkin s lymphoma (including hepatosplenic T-cell lymphoma in children on infliximab + azathioprine) Serious infections (~3%) Opportunistic infections (including tuberculosis, histoplasmosis, coccidiomycosis) Demyelination
33 When to Introduce Biologics? The Tipping Point may be Corticosteroids?
34 Challenges of Induction Maintenance 2009: Consider the Population Steroid-Naïve Steroid-Induction Thiopurine/MTX Maintenance (Markowitz) Anti-TNF Induction Thiopurine/MTX Maintenance (Step-up/Top-Down)
35 Challenges of Induction Maintenance 2009: Consider the Population Steroid-Dependent Thiopurine/MTX Maintenance (Candy, Markowitz, Feagan) Failure Biologic (ACCENT,CHARM,PREcISE)
36 Challenges of Induction Maintenance 2009: Consider the Population Steroid-Refractory Immunosuppressive naïve Steroid-Refractory Despite Immunosuppressive Anti-TNF + AZA induction & Maintenance (SONIC) Anti-TNF induction & Maintenance Stop Immunosuppressive Fail Assess Inflammation, Immunogenicity Switch Anti-TNF or Natlizumab
37 Current and Future Therapeutic Paradigms Current Bottom-up approach Conservative use of immunomodulators Goals Induce remission Maintain remission Prevent complications Optimize surgical outcomes Future Early aggressive approach Earlier use of immunomodulators Additional goals Disease modification Mucosal healing Pharmacoeconomics Disease prevention!
What are the Unmet Needs in the Management of IBD?
23/6/214 What are the Unmet Needs in the Management of IBD? Shane Devlin, MD, FRCPC Inflammatory Bowel Disease Group The University of Calgary Some Real Cases: #1 32 yo male with pan UC. Grumbling phenotype
More informationOptimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD )
Inflammatory Bowel Disease Center Optimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD ) Russell D. Cohen, M.D. F.A.C.G. A.G.A.F. Professor of Medicine, Pritzker Medical
More information11/10/2014. New Treatments in IBD: When, Whom and How. Background. Background. Options. Disease Assessment. What is the evidence?
New Treatments in IBD: When, Whom and How. Background Options Disease Assessment What is the evidence? Kofi Clarke MD, FACP,FRCP (Lond) Clinical Associate Professor, Chief, Gastroenterology, Hepatology
More informationEvidence of Crohn s Disease. Case Presentation
Witt Wait to Treat tutiled Until Endoscopic Evidence of Crohn s Disease Raymond Cross, MD, MS, AGAF Associate Professor of Medicine Director, IBD Program University of Maryland School of Medicine Co-Director,
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationREVIEW. Am J Gastroenterol advance online publication, 2 November 2010; doi:10.1038/ajg.2010.392
nature publishing group CLINICAL AND SYSTEMATIC S 1 The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn s and Colitis Organization:
More informationBriefing Document. Food and Drug Administration. Center for Drug Evaluation and Research
Briefing Document Food and Drug Administration Center for Drug Evaluation and Research Meeting: Joint Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
More informationTerapia con farmaci biologici e non nella. Sandro Ardizzone. Azienda Ospedaliera Fatebenefratelli e. Ospedale di Rilievo Nazionale Milan
Terapia con farmaci biologici e non nella Colite Ulcerosa Severa/Refrattaria Sandro Ardizzone Gastrointestinal Unit Azienda Ospedaliera Fatebenefratelli e Oftalmico Ospedale di Rilievo Nazionale Milan
More informationTREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER
Press information for journalists only TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER Why treat IBD? IBD describes a range of chronic diseases of the gastrointestinal system, encompassing Ulcerative
More informationDigestive and Liver Disease
Digestive and Liver Disease 43 (2011) 1 20 Contents lists available at ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Progress Report The Italian Society of Gastroenterology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationClinical experience of natalizumab in Crohn s disease patients in a restricted distribution program
Original article Annals of Gastroenterology (2013) 26, 1-6 Clinical experience of natalizumab in Crohn s disease patients in a restricted distribution program Chien-Huan Chen a, Gowri Kularatna a, Christian
More informationRheumatoid Arthritis:
Rheumatoid Arthritis Update 2014 Mark Hulsey, MD FACR Rheumatoid Arthritis Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis Palpable synovial
More informationOpportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
More informationMedical Therapy for IBD
CHILDREN S DIGESTIVE HEALTH & NUTRITION FOUNDATION NORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION Medical Therapy for IBD I. INTRODUCTION The treatment of Crohn s disease
More informationPHARMACOLOGIC MANAGEMENT FOR INFLAMMATORY BOWEL DISEASE: ULCERATIVE COLITIS & CROHN S DISEASE
PHARMACOLOGIC MANAGEMENT FOR INFLAMMATORY BOWEL DISEASE: ULCERATIVE COLITIS & CROHN S DISEASE Joseph Reilly, B.S., Pharm.D. Residency Program Director / Clinical Specialist AtlantiCare Regional Medical
More informationEffective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Tysabri (natalizumab) Policy #: 281 Latest Review Date: October
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationBiologic Therapy in Crohn s Disease: The Tricky Tincture of Timing
Biologic Therapy in Crohn s Disease: The Tricky Tincture of Timing Scott, Pharm.D. PGY1 Pharmacy Resident University Health System, San Antonio, TX Division of Pharmacotherapy, The University of Texas
More informationCan Rheumatoid Arthritis treatment ever be stopped?
Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship robdsimc@tampabay.rr.com Do not pour strange medicines
More informationAnti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
nature publishing group state Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms Ingrid Ordás 1,2, Diane R. Mould 3, Brian G. Feagan 4 and William J.
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationpåçííáëü=jéçáåáåéë=`çåëçêíáìã==
påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationAdult Inflammatory Bowel Disease Physician Performance Measures Set. August 2011*
Adult Inflammatory Bowel Disease Physician Performance Measures Set August 2011* *Last revised on October 26, 2011 American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationPatient Input Information Clinical Trials Outcomes Common Drug Review
CDEC FINAL RECOMMENDATION USTEKINUMAB (Stelara Janssen Inc.) Indication: Psoriatic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationDecision systems in quality registries
Decision systems in quality registries Stockholm Dec 9 th, 2014 Jonas Halfvarson, MD, PhD Dept of Gastronterology, Faculty of Medicine and Health, Örebro University 1 Quality registries for chronic diseases
More informationto Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.
2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title
More informationMultiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary
Multiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary OBJECTIVE The intent of the Multiple Sclerosis (MS) Agents Step Therapy (ST) program is to encourage the use of preferred multiple
More informationustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd
ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationMultiple Sclerosis Step Therapy and Quantity Limit Criteria
Multiple Sclerosis Step Therapy and Quantity Limit Criteria Tysabri (natalizumab) will NOT be included in this step therapy program for Blue Cross and Blue Shield of Illinois because this plan does not
More informationINFLAMMATORY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW
SPECIFICATION F MEASURES GROUP REPTING ONLY INFLAMMATY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW 2012 PHYSICIAN QUALITY REPTING OPTIONS F MEASURES GROUPS: REGISTRY ONLY 2012 PHYSICIAN QUALITY REPTING
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationTYSABRI (NATALIZUMAB)
CLINICAL POLICY TYSABRI (NATALIZUMAB) Policy Number: PHARMACY 154.10 T2 Effective Date: August 1, 2015 Table of Contents CONDITIONS OF COVERAGE... COVERAGE RATIONALE... BENEFIT CONSIDERATIONS... CLINICAL
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR THE TREATMENT OF ULCERATIVE COLITIS
European Medicines Agency London, 24 January 2008 Doc. Ref. CHMP/EWP/18463/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR THE TREATMENT
More informationRecognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationUse of biological molecules in the treatment of inflammatory bowel disease
Review doi: 10.1111/j.1365-2796.2011.02344.x Use of biological molecules in the treatment of inflammatory bowel disease O. H. Nielsen 1, J. B. Seidelin 1,L.K.Munck 2 &G.Rogler 3 From the 1 Department of
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationAnti-TNF Treatment in Inflammatory Bowel Disease
xx xx x xx x 48 ANNALS January OF GASTROENTEROLOGY 20, 2007, Kifisia, Athens, 2007, 20(1):48-53 Greece Lecture Anti-TNF Treatment in Inflammatory Bowel Disease Suna Yapali, Hulya Over Hamzaoglu INTRODUCTION
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationTYSABRI (natalizumab)
DRUG POLICY TYSABRI (natalizumab) Policy Number: 2015D0026K Effective Date: 8/1/2015 Table of Contents Page Related Medical or Drug Policies: None COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 2 CLINICAL
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationhttp://www.rxabbvie.com/pdf/humira.pdf (accessed 4/23/15)
Novel Treatment of Inflammatory Bowel Disease Informed by Science and Patient Choice Unanswered Questions March 11, 2015 Russell D. Cohen, MD, FACG, AGAF Medical marijuana in IBD 1. Unfortunately, with
More informationArthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationIssue date: August 2010
Issue date: August 2010 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Part review of NICE technology appraisal
More informationDAS28 criteria for initiation of biologics in early RA: a clinician s view. Dr Patrick Kiely St George s Healthcare NHS Trust, London
DAS28 criteria for initiation of biologics in early RA: a clinician s view Dr Patrick Kiely St George s Healthcare NHS Trust, London History: NICE (E&W) guidelines for starting anti-tnf agents April 2001
More informationHow long will it take to work? You may begin to feel better within a few days or it may take up to six weeks after your first treatment session.
Crohn's and Colitis UK Drug Treatment Information Improving life for people affected by inflammatory bowel diseases Infliximab This information leaflet aims to answer common questions you may have if you
More informationGuidelines for the Pharmaceutical Management of Rheumatoid Arthritis Swedish Society of Rheumatology, April 14, 2011
Guidelines for the Pharmaceutical Management of Rheumatoid Arthritis Swedish Society of Rheumatology, April 14, 2011 Working party: Eva Baecklund, Helena Forsblad d Elia, Carl Turesson Background Our purpose
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationImmunosuppressive drugs
Immunosuppressive drugs RJM ten Berge Afd. Inw. Geneeskunde AMC contents overview targets mechanism of action Effects on immune capacity measured by responses to vaccination Immune response 1 calcineurin
More informationCrohn s Disease. From research to bedside
Crohn s Disease From research to bedside Primary Care Of The Crohn s Disease Patient Primary Physician s Concerns Vaccination Cancer Cervical Skin Osteoporosis Problems Associated With Vaccinating The
More informationNew Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia
June 12, 2015 New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of
More informationRheumatoid Arthritis: Constantly Evolving Treatment Approaches
Rheumatoid Arthritis: Constantly Evolving Treatment Approaches Jody Garry, Pharm.D. Primary Care Pharmacy Resident VA Medical Center - Iowa City Presentation Overview Pathophysiology & epidemiology Diagnostic
More informationGuideline for the use of Biological Therapies in the Treatment of Psoriasis
1 Date of Production: March1 st 2011 Date of 1 st review: July 10 th 2015 Date for next review: March1 st 2018 Local Contact Dermatology Consultant Shanti Ayob Patient group to which this applies: Patients
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More informationUPDATED INVESTOR PRESENTATION June 2015
UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationGuidelines for the management of inflammatory bowel disease in adults
v1 GUIDELINES Guidelines for the management of inflammatory bowel disease in adults M J Carter, A J Lobo, S P L Travis, on behalf of the IBD Section of the British Society of Gastroenterology... Gut 2004;53(Suppl
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More informationMethods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,
More informationUnderstanding Colitis and Crohn s Disease
Improving life for people affected by Colitis and Crohn s Disease Understanding Colitis and Crohn s Disease 1 Understanding Colitis and Crohn s Disease Understanding Ulcerative Colitis and Crohn s Disease...
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationA New Era in Rheumatoid Arthritis Treatment
A New Era in Rheumatoid Arthritis Treatment Jill C. Costello, MD; Paul B. Halverson, MD ABSTRACT Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily manifests as a chronic symmetric
More informationManagement of Crohn s Disease in Adults
nature publishing group ACG PRACTICE GUIDELINES 1 Management of Crohn s Disease in Adults Gar y R. L ichtenste i n, M D 1 4, Ste phen B. Hanau e r, M D 1 4, Wi l l i am J. S andb or n, M D 1 3 and The
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More information1. Comparative effectiveness of alemtuzumab
Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued
More informationIn the last decade, there have been major changes in the
233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationUlcerative Colitis & Proctitis. About Ulcerative Colitis & Proctitis
Ulcerative Colitis & Proctitis About Ulcerative Colitis & Proctitis When you first learn that you have ulcerative colitis, you will probably feel overwhelmed. You may not even have heard of ulcerative
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationResearch in IBD at University of Colorado Denver
Research in IBD at University of Colorado Denver Blair Fennimore, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology UCH Crohn s and Colitis Center Mucosal Inflammation Program
More informationRecommendations for Early RA Patients
SUPPLEMENTARY APPENDIX 5: Executive summary of recommendations for patients with early RA, established RA, and high-risk comorbidities Recommendations for Early RA Patients We strongly recommend using
More informationRecognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
More informationimproving lives through collaborative medicine
improving lives through collaborative medicine ImproveCareNow is a collaborative chronic care network of 77 care centers in 35 states and the District of Columbia and England, where clinicians, researchers,
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationREMICADE (infliximab)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REMICADE safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab)
More informationI. Should All New Brunswickers be required to have drug coverage?
Crohn's and Colitis Foundation of Canada Fondation canadlenne des maladies Inflarnmatolres de l'lntestin 600-60 St. Clair Avenue East Toronto, ON Canada M4T INS Tel: (116) 'no.sols Fax: (416) 'n9-0364
More informationHow To Treat Colitis With A Combination Of Antibiotics
18 Simposio annuale ELAS-LIGAND LIGAND ASSAY 2012 LE MALATTIE INFIAMMATORIE INTESTINALI Aspetti Fisiopatologici e Clinici Giovanni Maconi Cattedra di Gastroenterologia Dipartimento di Scienze Biomediche
More informationManagement of Crohn s Disease in Adults
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 3, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)02234-1 PRACTICE GUIDELINES
More informationTuesday, July 23, 2013. Karen Hanson, RN, CNP Nurse Practitioner, Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN
Tuesday, July 23, 2013 Speakers Karen Hanson, RN, CNP Nurse Practitioner, Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN Susanne Benouna Medical Secretary, Division of Gastroenterology
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENTYVIO safely and effectively. See full prescribing information for ENTYVIO. ENTYVIO (vedolizumab)
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr REMICADE (Infliximab) This leaflet is part III of a three-part "Product Monograph" published when REMICADE was approved for sale in Canada and is designed specifically
More informationSECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
More informationAdalimumab for the treatment of psoriasis
DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments
More informationLet s talk about Arthritis
Let s talk about Arthritis Osteoarthritis Rheumatoid Arthritis Kam Shojania, MD, FRCPC Clinical Professor and Head, St. Paul s, UBC and VGH Divisions of Rheumatology Slides with thanks to: Cheryl Koehn
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More information